We are excited to welcome you to the inaugural issue of Cancer Research Communications, AACR’s newly launched open access journal that encompasses the full spectrum of cancer science and medicine. We encourage high-quality submissions that advance basic, translational, clinical, and population-based research spanning the full breadth of human cancers, and welcome manuscripts that integrate other disciplines such as engineering, physical sciences, mathematics, and computational biology into cancer research, thereby introducing new ideas to prevent and treat cancer. The mission of Cancer Research Communications is to be the global open forum for discovery, collaboration, and sharing of knowledge within the field of cancer research and beyond. The journal aims to rapidly disseminate scientific breakthroughs and technological innovations that improve cancer outcomes and develop cures.
The first four articles published by Cancer Research Communications embody these goals. Magistri and Happ et al. showcases genomic insights into a rare and understudied cancer, ocular adnexa MALT lymphoma, revealing molecular drivers through a combination of whole exome sequencing and copy number variation analyses. Looking at a more common malignancy, Parris et al. explore a potential vulnerability of NRAS mutant melanoma to synergistic inhibition of the kinase MEK and the protein folding chaperone HSP70. Also in the vein of uncovering new therapeutic approaches, Hanna et al. use immunoprofiling to establish PD-L1 as a biomarker of high risk of malignant transformation for benign oral leukoplakia, suggesting immune checkpoint blockade as a potential preventative treatment. Finally, Ando et al. tackle T cell exhaustion, a roadblock in the path of CAR-T cell therapies, by rejuvenating exhausted CAR-T cells to a proliferative and responsive state associated with higher anti-tumor activity by treating them with NOTCH ligand and the chemokine CXCL12. These excellent studies offer a sampling of the journal’s broad scope that we are eager to realize in coming months and years ahead.
The launch of a journal requires the concerted efforts and dedication of many individuals. We are thrilled to have assembled a top-notch senior editorial team consisting of world-renowned experts to lead nine major sections in Cancer Research Communications: Justin M. Balko, PhD (Vanderbilt University Medical Center, USA) for Immuno-Oncology; Sarat Chandarlapaty, MD, PhD (Memorial Sloan Kettering Cancer Center, USA) for Precision Medicine and Biomarkers; Joya Chandra, PhD (MD Anderson Cancer Center, USA) for Epidemiology and Prevention; Melissa B. Davis, PhD (Weill Cornell Medicine, USA) for Health Disparities and Outcomes Research; Maureen E. Murphy, PhD (The Wistar Institute Cancer Center, USA) for Molecular and Cellular Biology; Eileen M. O’Reilly, MD (Memorial Sloan Kettering Cancer Center, USA) for Clinical Research and Trials; Edna Cukierman, PhD (Fox Chase Cancer Center, USA) for Tumor Biology; Alex Sparreboom, PhD (The Ohio State University, USA) for Therapeutic Research and Development; and Alexander Swarbrick, PhD (Garvan Institute of Medical Research, Australia) for Emerging Technologies and Data Science. This outstanding team of Cancer Research Communications Senior Editors will work closely with a larger group of Associate Editors to deliver informative and expeditious peer review and to identify high-impact articles for priority publication.
We are also fortunate to have recruited two AACR editorial team members who are integral to the scientific and operational aspects of Cancer Research Communications. Lucas Brand, PhD serves as the Internal Associate Editor and Jennifer Zimmerman serves as the Managing Editor; both Lucas and Jennifer come with years of experience in manuscript evaluation, peer review systems, editorial processes, and author service.
Lastly, we thought we would end this first Cancer Research Communications Editors’ Corner with some quick-fire fun facts about ourselves:
Elaine R. Mardis, PhD (Nationwide Children’s Hospital, USA). A genomic scientist with a focus on incorporating genomics-guided precision medicine into the standard of care of pediatric cancer patients.
- What was the last book you read? Better Angels by Sadie Keller
- What would you have done if you weren’t in your current occupation? Chef
- Which scientist (alive or deceased) do you admire the most? Janet Rowley
- What do you like to do when you are not working on cancer research? Play golf
- Who is your favorite musician? Dave Grohl
- What is your favorite food? Catalan cuisine
Lillian L. Siu, MD (Princess Margaret Cancer Centre, Canada): A medical oncologist with research focus in experimental therapeutics, early phase clinical trials, and precision cancer medicine.
- What was the last book you read? The Double by José Saramago
- What would you have done if you weren’t in your current occupation? Architect
- Which scientist (alive or deceased) do you admire the most? Marie Curie
- What do you like to do when you are not working on cancer research? Travel
- Who is your favorite musician? Leonard Cohen
- What is your favorite food? Sushi and sashimi
We look forward to considering your work in the pages of Cancer Research Communications! If you have any questions about the scope of the journal, our editorial ethos and processes, or how to submit your work, please do not hesitate to contact us at email@example.com.
Elaine R. Mardis, PhD
Lillian L. Siu, MD